Neurocity S.R.L.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• CIDP (chronic inflammatory demyelinating polyneuropathy)2 trials
• Huntington's disease1 trial
• Lupus (SLE)1 trial
• Multiple sclerosis1 trial
• Myasthenia gravis1 trial

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Recruiting4 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• argenx2 trials
• Novartis Pharmaceuticals2 trials
• EMD Serono Research & Development Institute, Inc.1 trial
• Novartis Pharma AG1 trial

Running trials

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Active, not recruiting

  A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

  NCT04280718· Phase 2· argenx· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Huntington's disease1 recruiting
• Lupus (SLE)1 recruiting
• Multiple sclerosis1 recruiting

Closed trials

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source